Abstract
The most desirable treatment for multiple sclerosis (MS) would safely arrest the disease process before clinical signs and symptoms had appeared. This has not yet been achieved. Failing this, one would wish safely to arrest or reverse its course as soon as possible after its earliest clinical manifestations. This chapter will present the results of two pilot trials of a synthetic product, Copolymer I (Cop 1), which show promise of attaining the second objective.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Abramsky O, Teitelbaum D, Arnon R (1977) Effect of a synthetic polypeptide (Cop 1) on patients with multiple sclerosis and acute disseminated encephalomyelitis: Preliminary report. J Neurol Sci 31: 433–438
Anderson S, Auguier A, Hauck W et al. (1980) Statistical methods for comparative studies. John Wiley and Sons, USA, pp 199–214
Appel SH, Bornstein MB, Seegal BC, Murray MR (1962) The application of tissue culture to the study of experimental “allergic” encephalomyelitis. II. Immunological observations. Proc Int Cong Neuropath 2: 283
Arnon R (1981) Experimental allergic encephalomyelitis — susceptibility and suppression. Immunol Rev 55: 5–30
Arnon R, Teitelbaum D (1980) Desensitization of experimental allergic encephalomyelitis with synthetic peptide analogues. In: Davison AN, Cuzner ML (eds) The suppression of experimental allergic encepahlomyelitis and multiple sclerosis. Academic Press, New York, pp 105–117
Barsumian EL, Isersky C, Petrino MG et al. (1981) IgE-induced histamine release from rat basophilic leukemia cell lines: Isolation of releasing and nonreleasing clones. Eur J Immunol 11: 317–323
Bornstein MB (1963) A tissue culture approach to demyelinative disorders. Nat Cancer Inst Monogr 11: 197–214
Bornstein MB (1973) The immunopathology of demyelinating disorders examined in organotypic cultures of mammalian central nerve tissue. In: HM Zimmerman (ed) Progress in neuropathology, vol 2. Grune and Stratton, New York, pp 69–90
Bornstein MB, Appel SH (1961) The application of tissue culture to the study of experimental “allergic” encephalomyelitis. I. Patterns of demyelination. J Neuropath Exp Neurol 20: 141–157
Bornstein MB, Raine CS (1976) The initial structural lesion in serum-induced demyelination in vitro. Lab Invest 35: 391–401
Bornstein MB, Raine CS (1977) Multiple sclerosis and experimental allergic encephalomyelitis. Specific demyelination of CNS in culture. Neuropathology Applied Neurobiology 3: 359–367
Bornstein MB, Miller A, Slagle S et al. (1987) A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 317: 408–414
Bornstein MB, Miller A, Slagle S et al. (1991) A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive-multiple sclerosis. Neurology 41: 533–539
Hauser L, Dawson DM, Lehrich JR et al. (1983) Intense immunosuppression in progressive multiple sclerosis. N Engl J Med 308: 173–180
Keith AB, Arnon R, Teitelbaum D et al. (1979) The effect of Cop 1, a synthetic polypeptide, on chronic relapsing experimental allergic encephalomyelitis in guinea pigs. J Neurol Sci 42: 267–274
Kurtzke JF (1983) Rating neurological impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 33: 1444–1452
Lando Z, Teitelbaum D, Arnon R (1979) Effect of cyclophosphamide on suppressor cell activity in mice unresponsive to EAE. J Immunol 123: 2156–2160
Paterson PY (1977) Autoimmune neurologic disease: Experimental animal systems and implications for multiple sclerosis. In: Talmage N (ed) Autoimmunity: Genetic, immunologic, virologic and clinical aspects. Academic Press, New York, pp 643–692
Paterson PY (1978) The demyelinating diseases: Clinical and experimental studies in animals and man. In: Samter M, Alexander N, Rose B, Sherman WB, Talmage DW, Vaughn JH (eds) Immunologic diseases, 3rd edn. Little, Brown and Company, Boston, pp 1400–1435
Paterson PY (1979) Neurological disorders. In: WJ Irvine (ed) Medical immunology. Teviot Scientific Publications, Edinburgh, pp 361–381
Paterson PY (1980) The immunopathology of experimental allergic encephalomyelitis. In: Davison AN, Cuzner MC (eds) The suppression of experimental allergic encephalomyelitis in multiple sclerosis. Academic Press, New York, pp 11–30
Poser CM, Patty DW, Scheinberg L et al. (1983) New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 13: 227–231
Raine CS, Bornstein MB (1970) Experimental allergic encephalomyelitis. A light and electron microscope study of remyelination and “sclerosis” in vitro. J Neuropath Exp Neurol 29: 552–574
Raine CS, Bornstein MB (1979) Experimental allergic neuritis ultrastructure of serum-induced myelin aberrations in PNS cultures. Lab Invest 40: 423–432
Teitelbaum D, Meshorer A, Hirshfeld T et al. (1971) Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1: 242–248
Teitelbaum D, Webb C, Meshorer A et al. (1973) Suppression by synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen. Eur J Immunol 3: 273–279
Teitelbaum D, Webb C, Bree M et al. (1974) Suppression of experimental allergic encephalomyelitis in rhesus monkeys by a synthetic basic copolymer. Clin Immunol Immunopathol 3: 256–262
Webb C, Teitelbaum D, Arnon R et al. (1973) In vivo and in vitro immunological cross-reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing experimental allergic encephalomyelitis. Eur J Immunol 3: 279–286
Webb C, Teitelbaum D, Herz A et al. (1976) Molecular requirements involved in suppression of EAE by synthetic basic copolymers of amino acids. Immunochemistry 13: 333–337
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer-Verlag London Limited
About this chapter
Cite this chapter
Bornstein, M.B., Johnson, K.P. (1992). Treatment of Multiple Sclerosis with Copolymer I. In: Rudick, R.A., Goodkin, D.E. (eds) Treatment of Multiple Sclerosis. Clinical Medicine and the Nervous System. Springer, London. https://doi.org/10.1007/978-1-4471-3184-7_8
Download citation
DOI: https://doi.org/10.1007/978-1-4471-3184-7_8
Publisher Name: Springer, London
Print ISBN: 978-1-4471-3186-1
Online ISBN: 978-1-4471-3184-7
eBook Packages: Springer Book Archive